Clinical Trial Update: Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated the combination of bortezomib and temozolomide in adults with advanced refractory solid tumors or melanoma; the trial was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors
• Melanoma
• Solid Tumors

Drugs mentioned

• Temodar (Temozolomide)
• Velcade (bortezomib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Brain and Central Nervous System Tumors, Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-08-03